

JC06 Rec'd PCT/PTO 07 APR 2005

FORM PTO-1449 (modified) To: U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No. 056291-5203	Client Ref. 10/530567
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Alan BARGE	
		Appl. No.: Unassigned	
		Filing Date: April 7, 2005	
Date: April 7, 2005	Page 1 of 1	Examiner: Unassigned	Group Art Unit: Unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
AR						
BR						
CR						

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclosed	No
	DR	04/32654	05/2001	WO	Hennequin et al.				
	ER								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	FR	Giardiello et al., Antitumor Effects of ZD6474, A Small Molecule VEGF Receptor-Tyrosine Kinase Inhibitor That Is Also Active Against EGF Receptor Tyrosine Kinase, Proceedings of the American Association for Cancer Research Annual Vol. 43, March 2002, pp. 1080-1081.			
	GR	Breys et al., Effect of ZD6474, A VEGF Receptor Tyrosine Kinase Inhibitor, on Primary Tumor Growth, Metastasis, Vessel Density and Microvascular Architecture in Murine Renal Cell Carcinoma, Proceedings of the American Association for Cancer Research Annual, Vol. 43, March 2002, pp. 1082.			
	HR	Wedge et al., Combination of the VEGF Receptor Tyrosine Kinase Inhibitor ZD6474 and Vascular Targeting Agent ZD6126 Produced an Enhanced Antitumor Response, Proceedings of the American Association for Cancer Research Annual, Vol. 43, March 2002, pp. 1081.			
	IR	Holden et al., Effects of ZD6474, An Orally Active Inhibitor of VEGF Receptor Tyrosine Kinase, in Patients With Solid Tumors: Results From A Phase I Study, European Journal of Cancer, Pergamon Press, Vol. 37, No. Supplement 6, October 2001, pp. S73.			
	JR	Hennequin et al., Novel 4-Anilinoquinazolines With C-7 Basic Side Chains: Design and Structure Activity Relationship Of A Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors, Journal Of Medicinal Chemistry, American Chemical Society, Vol. 45, No. 6, March 14, 2002, pp. 1308-1312.			
	KR	Glanccone et al., ZD1839 ("Iressa"), An Orally Active, Selective, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (egfr-kti), Is Well Tolerated In Combination With Gemcitabine And Cisplatin, In Patients With Advanced Solid Tumours: Preliminary Tolerability, Efficacy And Pharmacokinetic Results, European Journal of Cancer, Vol. 37, No. Supplement 6, October 2001, pp. S30-S34.			
	LR				

Examiner /Meghan Finn/	Date Considered: 11/18/2007
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.	